|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-3-26
|
|
pubmed:abstractText |
Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/KRAS protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BetticherD CDC,
pubmed-author:BihlMM,
pubmed-author:BubendorfLL,
pubmed-author:D'AddarioGG,
pubmed-author:JostLL,
pubmed-author:LerchSS,
pubmed-author:MackKK,
pubmed-author:MayerMM,
pubmed-author:PlessMM,
pubmed-author:RauchDD,
pubmed-author:RibiKK,
pubmed-author:StahelRR,
pubmed-author:StuppRR,
pubmed-author:TapieGG,
pubmed-author:WidmerLL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
739-45
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18096565-Adult,
pubmed-meshheading:18096565-Aged,
pubmed-meshheading:18096565-Aged, 80 and over,
pubmed-meshheading:18096565-Analysis of Variance,
pubmed-meshheading:18096565-Antineoplastic Agents,
pubmed-meshheading:18096565-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18096565-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18096565-Cisplatin,
pubmed-meshheading:18096565-Deoxycytidine,
pubmed-meshheading:18096565-Disease Progression,
pubmed-meshheading:18096565-Drug Administration Schedule,
pubmed-meshheading:18096565-Female,
pubmed-meshheading:18096565-Humans,
pubmed-meshheading:18096565-In Situ Hybridization, Fluorescence,
pubmed-meshheading:18096565-Kaplan-Meier Estimate,
pubmed-meshheading:18096565-Lung Neoplasms,
pubmed-meshheading:18096565-Male,
pubmed-meshheading:18096565-Middle Aged,
pubmed-meshheading:18096565-Mutation,
pubmed-meshheading:18096565-Neoplasm Staging,
pubmed-meshheading:18096565-Protein Kinase Inhibitors,
pubmed-meshheading:18096565-Proto-Oncogene Proteins,
pubmed-meshheading:18096565-Quality of Life,
pubmed-meshheading:18096565-Questionnaires,
pubmed-meshheading:18096565-Quinazolines,
pubmed-meshheading:18096565-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18096565-Risk Assessment,
pubmed-meshheading:18096565-Risk Factors,
pubmed-meshheading:18096565-Smoking,
pubmed-meshheading:18096565-Switzerland,
pubmed-meshheading:18096565-Treatment Outcome,
pubmed-meshheading:18096565-ras Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
|
|
pubmed:affiliation |
Department of Oncology, Kantonsspital St.Gallen, St. Gallen, Switzerland. g.daddario@hin.ch
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
